2+ concentration in SGC-7901 and GES-1 cells. After staining with Fluo-3 AM, cells were incubated with hispidin and assayed for fluorescence for 90 min using a Microplate Reader. (B) SGC-7901 cells were treated with 122 mM hispidin or 0.1% DMSO in growth medium with different concentrations of calcium for 24 h and assayed for cell viability using the MTT assay. SGC-7901 cells were preincubated with heparin (1, 5, 10, or 100 µg/mL) (C) or procaine (0.1, 0.5, 1, or 10 mM) (D) for 2 h. Then, the cells were treated with 122 μM hispidin or 0.1% DMSO for 24 h, and cell viability was measured using the MTT assay. (E) SGC-7901 cells were incubated with 122 μM hispidin or 0.1% DMSO and then were assayed for SERCA activity.
After staining with DCFH-DA, SGC-7901 cells (A) and GES-1 cells (B) were incubated with hispidin and assayed for fluorescence for 90 min using a Microplate Reader. (C) After being incubated with 122 μM hispidin or 0.1% DMSO for 0.5, 1, 2, 3 h, the SGC-7901 and GES-1 cells were assayed for JC-1 low cells. (D) After being incubated with different concentrations of hispidin for 3 h, GSH levels in SGC-7901 and GES-1 cells were assayed. (E) Purified GCS was incubated with 20 to 325 µM hispidin and assayed for GCS activity. (F) SGC-7901 and GES-1 cells were incubated with 122 μM hispidin or 0.1% DMSO for 1, 3, and 6 h, and then γ-GCS was detected by Western blotting using β-actin as an internal control.
